Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists
January 21 2021 - 07:00AM
Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its
thought leadership capabilities with the addition of several new
Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a
board-certified radiologist with clinical expertise in
Interventional Radiology with a focus in Tumor Ablation; Ajay K.
Wakhloo, MD PhD FAHA, an internationally recognized expert in acute
stroke therapy and the isolation of intracranial aneurysms and
arteriovenous malformations; Gal Yaniv, MD, PhD, an endovascular
neurosurgeon and leading authority on Artificial Intelligence;
Dmitry J. Rabkin, MD, PhD, FSIR, a vascular and Interventional
Radiology Specialist; and Ziv Neeman, MD, a vascular and
interventional radiology clinician and researcher with a wide array
of expertise, particularly in the field of navigation systems for
minimally invasive image-guided interventional procedures.
“As we continue to develop and perfect our novel
technologies, it remains critical that we also attract
extraordinary capabilities throughout the organization -
management, Board of Directors and Scientific Advisory Board - to
leverage their combined expertise to achieve Microbot Medical’s
objectives,” commented Harel Gadot, CEO, President and Chairman.
“We are expecting a higher level of activity in the next year,
including significant clinical and regulatory milestones, so our
ability to attract leading talent and capitalize on their successes
should enable us to maintain a competitive advantage and be at the
forefront of developing innovative technologies to address the
healthcare industry’s unmet medical needs.”
- Stephen B. Solomon,
MD is Chief of the Interventional Radiology Service at
Memorial Sloan Kettering, where he also holds the Enid A. Haupt
Chair in Clinical Investigation. He is Director of Memorial Sloan
Kettering’s Center for Image-Guided Interventions and leads a
research lab that works to improve image-guided cancer
interventions. He treats kidney cancer, liver cancer, lung cancer
and bone cancer, has an interest in treating tumors with thermal
ablation and performs hepatic artery embolization. Dr. Solomon was
named a Castle Connolly: New York Magazine Top Doctor from
2012-2013 and 2015-2020. He received his undergraduate degree from
Harvard, medical degree from Yale School of Medicine, and completed
residencies at Yale-New Haven Hospital and The John Hopkins
Hospital.
- Gal Yaniv, MD, PhD
is a founder and the Chief Medical Officer at Aidoc, contributing
his expertise and knowledge to help in the continuing development
of advanced, healthcare grade AI. He is currently the Director,
Endovascular Neurosurgery unit at Sheba – Tel HaShomer hospital. A
double graduate (M.D, PhD, cum laude on both) of the Technion –
Israel Institute of Technology, Dr. Yaniv completed his radiology
residency at Sheba, Tel HaShomer hospital as well as diagnostic
neuroradiology fellowship at Yale School of Medicine and
endovascular neurosurgery fellowship at Mount Sinai Hospital. He
has published numerous scientific publications focusing on basic
science, radiology and public health, including a recent
publication at the New England Journal of Medicine, and has
presented in various scientific conferences worldwide. As a
“Talpiot” alumni, he participates in the “Talpiot Medical
Leadership Program” at Tel HaShomer Hospital.
- Dmitry J. Rabkin, MD, PhD,
FSIR is a Vascular and Interventional Radiology
Specialist, who is currently the Assistant Professor of Radiology
at the Harvard Medical School and Assistant Chief of the Division
of Interventional Radiology at the Brigham and Women's Hospital.
Previously, he was a Clinical Director and Chief of the Division of
Interventional Radiology at the Beth Israel Deaconess Medical
Center, HMS, where he completed his residency in Diagnostic
Radiology and a fellowship in Vascular and Interventional
Radiology. He graduated from the First Moscow Medical School. Based
on his achievements and contributions to the specialty, Dr. Rabkin
has been elected to Fellowship of the Society of Interventional
Radiology. Dr. Rabkin has been recognized as a Castle Connolly Top
Doctor and Boston Magazine Top Doctor since 2016 for his
professional qualifications, reputation and clinical skills in the
field of Interventional Radiology.
- Ajay K. Wakhloo, MD, PhD,
FAHA is certified by the American Board of Radiology in
Neuroradiology and Diagnostic Radiology, and he currently serves as
Chief of Neurointerventional Radiology and Professor at TUFTS
University School of Medicine. Prior to Tufts, he was a tenured
Professor of Radiology, Neurology and Neurosurgery and the
Director, Division NeuroImaging and Intervention (NII) in the
Department of Radiology, University of Massachusetts Medical
School. Earlier in his career, Dr. Wakhloo was a tenured Professor
of Radiology, Neurological Surgery and Biomedical Engineering in
the Department of Radiology at the University of Miami, Miller
School of Medicine. He received both his medical degree and Ph.D.
from the University of Mainz, Germany and completed his Internship
and Residency in Internal Medicine at the University of Mainz. His
training was continued at the University of Freiburg, Germany in
diagnostic and interventional Neuroradiology. He also completed
fellowships in Neurosurgery at the University of Freiburg and
Endovascular Neurosurgery at SUNY Buffalo, as well as Research
Fellowships in Neurological Surgery at Barrow Neurological
Institute and in Neurosurgery at SUNY Buffalo.
- Ziv
Neeman, MD is the Director of the Diagnostic Imaging
Institute and Nuclear Medicine at the Haemek Medical Center (Afula,
Israel). He is affiliated with the Ruth & Bruce Rapport Faculty
of Medicine (Technion, Israel) as Clinical Assistant Professor in
the Diagnostic Radiology Department, where he trains medical
students in the field of Diagnostic Imaging. He also serves as a
guideline task force member for the European Society of
Gastrointestinal Endoscopy. Dr. Neeman completed fellowships at
Beth Israel Deaconess (Abdominal Imaging) and Georgetown University
medical center (Interventional radiology). Prior clinical roles
include Section Chief of Interventional Oncology in the Diagnostic
Radiology Department at the National Institutes of Health (NIH)
Clinical Center (Bethesda, MD), and Chairman of the Diagnostic
Imaging Institute at the Haemek Medical Center. He was a partner at
Diagnostic Imaging Inc. (Philadelphia, PA), where he practiced
vascular and interventional radiology, interventional oncology and
diagnostic radiology. He has held academic appointments in the
Diagnostic Radiology Departments at both the NIH, and the
University of Maryland Medical Center (Baltimore, MD). Over the
span of his career, Dr. Neeman has published dozens of academic and
clinical research articles in peer reviewed journals and serves as
an ad hoc reviewer. He is a graduate of Ben Gurion University of
the Negev Faculty of Health Sciences medical school, and completed
an Abdominal Imaging fellowship at the Beth Israel Deaconess
Medical Center (affiliated to the Harvard Medical School), Boston,
MA and an Interventional and Vascular Radiology fellowship at the
Georgetown University Medical Center, Washington, D.C, and is
currently a member of the Israel Medical Association, the Israel
Radiology Association and the Radiological Society of North America
(RSNA).
The new SAB members join a renowned panel of
neurosurgeons and thought leaders in robotic medical technologies,
including Prof. Moshe Shoham. Prof. Shoham is the co-founder of
Microbot Medical and founder of Mazor Robotics. The Company
believes that the combined contributions from their diverse sets of
expertise will help drive development of next generation robotic
endoluminal surgery devices targeting the minimally invasive
surgery space.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY™ and SCS, the outcome of its studies to evaluate
LIBERTY, SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2023 to Mar 2024